Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (5)	9/22/2000 6:35:11 PM
From: Bernie Bildman	Read Replies (1) \| Respond to of 278

I doubt there is any connection between the legal stuff and what is going on now. My best bet scenario is that Globomax simply was going over the data, ONE MORE TIME, and realized there was a link or something missing. Maybe it has to do with the fact that the first IND will probably be a topical agent and they needed more data on the 'carrier' of the R ingredient. Or maybe they decided to use another one. Or decided to submit MORE than one IND to begin with, and wanted all data for ALL initial submissions done NOW. it's possible they had it all 'in the can' and asked one more fellow at Globomax to go over it, that perhaps is not involved in the process. Maybe he saw something they did not. In any case, what I'm saying is that...ther's no way _WE'RE_ gonna know WHY. What do you think about my projections about having fast track vs no fast track? What do you think will happen is the IND get approved, but NO fast track??